Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada; Cardiac Sciences Program, Winnipeg Regional Health Authority and St. Boniface Hospital, Winnipeg, Manitoba, Canada.
Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Int J Surg. 2015 Nov;23(Pt B):280-284. doi: 10.1016/j.ijsu.2015.07.009. Epub 2015 Jul 17.
The transplantation (implantation) of xenograft heart valves into humans has been carried out for >50 years. There has been considerable research into making this form of xenotransplantation successful, though it is not perfect yet. We review the understanding of the immune response to xenograft heart valves. Important steps in the history include understanding (i) the importance of glutaraldehyde in decreasing the immune response and (ii) the relationship between calcification (which is the main problem leading to xenograft failure) and the immune response. We subsequently discuss the importance of identifying xenoantigens that are important in leading to xenograft valve failure, and the potential of genetically-engineered pigs to allow the development of the 'ideal' heart valve for clinical valve replacement.
将异种移植物心脏瓣膜移植(植入)入人体已经超过 50 年。人们已经进行了大量的研究来使这种形式的异种移植成功,但它还不完善。我们回顾了对异种移植物心脏瓣膜免疫反应的理解。历史上的重要步骤包括理解(i)戊二醛在降低免疫反应中的重要性,以及(ii)钙化(导致异种移植物失败的主要问题)与免疫反应之间的关系。随后,我们讨论了确定导致异种移植物瓣膜失败的重要异种抗原的重要性,以及基因工程猪的潜力,这可以为临床瓣膜置换开发“理想”的心脏瓣膜。